Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including:
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
